Published in J Biol Chem on June 20, 2013
Loss of oncogenic Notch1 with resistance to a PI3K inhibitor in T-cell leukaemia. Nature (2014) 1.55
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: targeting the unfolded protein response signaling. Leukemia (2013) 1.02
The emerging roles of Notch signaling in leukemia and stem cells. Biomark Res (2013) 0.90
Notch1 Mutation Leads to Valvular Calcification Through Enhanced Myofibroblast Mechanotransduction. Arterioscler Thromb Vasc Biol (2015) 0.82
Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia. Oncotarget (2015) 0.80
The Interplay between PP2A and microRNAs in Leukemia. Front Oncol (2015) 0.79
Ack1 overexpression promotes metastasis and indicates poor prognosis of hepatocellular carcinoma. Oncotarget (2015) 0.77
The broken "Off" switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clin (2016) 0.77
Post-transcriptional modulation of protein phosphatase PPP2CA and tumor suppressor PTEN by endogenous siRNA cleaved from hairpin within PTEN mRNA 3'UTR in human liver cells. Acta Pharmacol Sin (2016) 0.76
Targeting Notch1 and proteasome as an effective strategy to suppress T-cell lymphoproliferative neoplasms. Oncotarget (2015) 0.76
Aberrant Signaling Pathways in T-Cell Acute Lymphoblastic Leukemia. Int J Mol Sci (2017) 0.75
A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res (2001) 124.61
Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science (2004) 18.84
The canonical Notch signaling pathway: unfolding the activation mechanism. Cell (2009) 14.72
PHLPP: a phosphatase that directly dephosphorylates Akt, promotes apoptosis, and suppresses tumor growth. Mol Cell (2005) 8.22
HES and HERP families: multiple effectors of the Notch signaling pathway. J Cell Physiol (2003) 7.32
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth. Proc Natl Acad Sci U S A (2006) 6.80
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat Med (2007) 6.55
PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell (2007) 6.00
Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol (2009) 4.89
PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol (2009) 4.83
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors. Nat Genet (2000) 3.82
Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta (2008) 3.74
Notch signaling in leukemia. Annu Rev Pathol (2008) 3.21
PP2A holoenzyme assembly: in cauda venenum (the sting is in the tail). Trends Biochem Sci (2008) 3.04
The Hes gene family: repressors and oscillators that orchestrate embryogenesis. Development (2007) 2.92
PTEN posttranslational inactivation and hyperactivation of the PI3K/Akt pathway sustain primary T cell leukemia viability. J Clin Invest (2008) 2.68
Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes. Immunity (2000) 2.58
Long-term outcome in children with relapsed acute lymphoblastic leukemia after time-point and site-of-relapse stratification and intensified short-course multidrug chemotherapy: results of trial ALL-REZ BFM 90. J Clin Oncol (2010) 2.53
Differential inhibition and posttranslational modification of protein phosphatase 1 and 2A in MCF7 cells treated with calyculin-A, okadaic acid, and tautomycin. J Biol Chem (1997) 2.40
Regulation of phosphorylation of Thr-308 of Akt, cell proliferation, and survival by the B55alpha regulatory subunit targeting of the protein phosphatase 2A holoenzyme to Akt. J Biol Chem (2007) 2.36
Notch signals positively regulate activity of the mTOR pathway in T-cell acute lymphoblastic leukemia. Blood (2007) 2.29
Long-term results of St Jude Total Therapy Studies 11, 12, 13A, 13B, and 14 for childhood acute lymphoblastic leukemia. Leukemia (2009) 2.24
FoxO transcription factors activate Akt and attenuate insulin signaling in heart by inhibiting protein phosphatases. Proc Natl Acad Sci U S A (2007) 2.08
Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol (2006) 2.00
The anti-apoptotic effect of Notch-1 requires p56lck-dependent, Akt/PKB-mediated signaling in T cells. J Biol Chem (2003) 1.96
Physiological regulation of Akt activity and stability. Am J Transl Res (2010) 1.95
PHLiPPing the switch on Akt and protein kinase C signaling. Trends Endocrinol Metab (2008) 1.92
NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. Blood (2008) 1.84
B56-containing PP2A dephosphorylate ERK and their activity is controlled by the early gene IEX-1 and ERK. EMBO J (2006) 1.71
PP2A impaired activity is a common event in acute myeloid leukemia and its activation by forskolin has a potent anti-leukemic effect. Leukemia (2011) 1.59
Role of Deltex-1 as a transcriptional regulator downstream of the Notch receptor. J Biol Chem (2001) 1.56
The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia (2010) 1.56
Asymmetric cancer cell division regulated by AKT. Proc Natl Acad Sci U S A (2011) 1.52
CSL-MAML-dependent Notch1 signaling controls T lineage-specific IL-7R{alpha} gene expression in early human thymopoiesis and leukemia. J Exp Med (2009) 1.47
The bHLH gene Hes1 regulates differentiation of multiple cell types. Mol Cells (2000) 1.47
The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group. Leukemia (2009) 1.45
The level of AKT phosphorylation on threonine 308 but not on serine 473 is associated with high-risk cytogenetics and predicts poor overall survival in acute myeloid leukaemia. Leukemia (2009) 1.38
Notch in T-ALL: new players in a complex disease. Trends Immunol (2011) 1.35
High-level IGF1R expression is required for leukemia-initiating cell activity in T-ALL and is supported by Notch signaling. J Exp Med (2011) 1.31
PP2A regulatory subunit PP2A-B' counteracts S6K phosphorylation. Cell Metab (2010) 1.29
Genetic rearrangements in relation to immunophenotype and outcome in T-cell acute lymphoblastic leukaemia. Best Pract Res Clin Haematol (2010) 1.22
Inhibition of B56-containing protein phosphatase 2As by the early response gene IEX-1 leads to control of Akt activity. J Biol Chem (2007) 1.22
Suppression of AMPK activation via S485 phosphorylation by IGF-I during hyperglycemia is mediated by AKT activation in vascular smooth muscle cells. Endocrinology (2011) 1.21
Posttranscriptional deregulation of MYC via PTEN constitutes a major alternative pathway of MYC activation in T-cell acute lymphoblastic leukemia. Blood (2011) 1.20
Clk2 and B56β mediate insulin-regulated assembly of the PP2A phosphatase holoenzyme complex on Akt. Mol Cell (2011) 1.18
Adiponectin-activated AMPK stimulates dephosphorylation of AKT through protein phosphatase 2A activation. Cancer Res (2009) 1.15
Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc (2010) 1.15
Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther (2006) 1.10
Hijacking HES1: how tumors co-opt the anti-differentiation strategies of quiescent cells. Trends Mol Med (2009) 1.07
Notch-1 regulates Akt signaling pathway and the expression of cell cycle regulatory proteins cyclin D1, CDK2 and p21 in T-ALL cell lines. Leuk Res (2008) 1.06
Regulation of PTEN by CK2 and Notch1 in primary T-cell acute lymphoblastic leukemia: rationale for combined use of CK2- and gamma-secretase inhibitors. Haematologica (2009) 0.99
Reciprocal regulation of Notch and PI3K/Akt signalling in T-ALL cells in vitro. J Cell Biochem (2008) 0.99
PP2A mediated AMPK inhibition promotes HSP70 expression in heat shock response. PLoS One (2010) 0.93
Circumventing cellular control of PP2A by methylation promotes transformation in an Akt-dependent manner. Neoplasia (2012) 0.87
Downregulation of Notch signaling by gamma-secretase inhibition can abrogate chemotherapy-induced apoptosis in T-ALL cell lines. Ann Hematol (2008) 0.87
Methylation of the C-terminal leucine residue of the PP2A catalytic subunit is unnecessary for the catalytic activity and the binding of regulatory subunit (PR55/B). Biochem Biophys Res Commun (2007) 0.86
Autophosphorylation-activated protein kinase inactivates the protein tyrosine phosphatase activity of protein phosphatase 2A. FEBS Lett (1994) 0.83
AKT down-regulates insulin-like growth factor-1 receptor as a negative feedback. J Biochem (2011) 0.82
γ-Secretase-regulated signaling pathways, such as notch signaling, mediate the differentiation of hematopoietic stem cells, development of the immune system, and peripheral immune responses. Curr Stem Cell Res Ther (2011) 0.81
Down-regulation of c-Myc and Max genes is associated to inhibition of protein phosphatase 2A in K562 human leukemia cells. Biochem Biophys Res Commun (1995) 0.77
A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481. Blood (2006) 2.58
Membrane transporters and folate homeostasis: intestinal absorption and transport into systemic compartments and tissues. Expert Rev Mol Med (2009) 2.33
Fecal collection, ambient preservation, and DNA extraction for PCR amplification of bacterial and human markers from human feces. J Microbiol Methods (2007) 1.77
An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia. Cancer Cell (2012) 1.61
Synthesis and discovery of high affinity folate receptor-specific glycinamide ribonucleotide formyltransferase inhibitors with antitumor activity. J Med Chem (2008) 1.54
Association between prenatal pesticide exposures and the generation of leukemia-associated T(8;21). Pediatr Blood Cancer (2007) 1.54
Rodent intestinal folate transporters (SLC46A1): secondary structure, functional properties, and response to dietary folate restriction. Am J Physiol Cell Physiol (2007) 1.52
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia. Blood (2005) 1.51
Risk for leukemia in infants without Down syndrome who have transient myeloproliferative disorder. J Pediatr (2006) 1.48
GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia. J Natl Cancer Inst (2005) 1.41
Comparative analysis of different approaches to measure treatment response in acute myeloid leukemia. J Clin Oncol (2012) 1.30
Down syndrome and malignancies: a unique clinical relationship: a paper from the 2008 william beaumont hospital symposium on molecular pathology. J Mol Diagn (2009) 1.29
Acute T-cell leukemias remain dependent on Notch signaling despite PTEN and INK4A/ARF loss. Blood (2009) 1.23
RUNX1 regulates phosphoinositide 3-kinase/AKT pathway: role in chemotherapy sensitivity in acute megakaryocytic leukemia. Blood (2009) 1.22
Targeting the proton-coupled folate transporter for selective delivery of 6-substituted pyrrolo[2,3-d]pyrimidine antifolate inhibitors of de novo purine biosynthesis in the chemotherapy of solid tumors. Mol Pharmacol (2010) 1.21
The human reduced folate carrier gene is ubiquitously and differentially expressed in normal human tissues: identification of seven non-coding exons and characterization of a novel promoter. Biochem J (2002) 1.21
The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem (2003) 1.20
Activity of dendrimer-methotrexate conjugates on methotrexate-sensitive and -resistant cell lines. Bioconjug Chem (2006) 1.19
Mutational spectrum at GATA1 provides insights into mutagenesis and leukemogenesis in Down syndrome. Blood (2009) 1.18
The human proton-coupled folate transporter: Biology and therapeutic applications to cancer. Cancer Biol Ther (2012) 1.16
Cardiomyopathy in children with Down syndrome treated for acute myeloid leukemia: a report from the Children's Oncology Group Study POG 9421. J Clin Oncol (2008) 1.15
Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome. Blood (2004) 1.13
Therapeutic targeting of a novel 6-substituted pyrrolo [2,3-d]pyrimidine thienoyl antifolate to human solid tumors based on selective uptake by the proton-coupled folate transporter. Mol Pharmacol (2011) 1.12
Mechanisms of synergistic antileukemic interactions between valproic acid and cytarabine in pediatric acute myeloid leukemia. Clin Cancer Res (2010) 1.11
Structure and regulation of the murine reduced folate carrier gene: identification of four noncoding exons and promoters and regulation by dietary folates. J Biol Chem (2004) 1.11
Haploinsufficiency in DNA polymerase beta increases cancer risk with age and alters mortality rate. Cancer Res (2006) 1.08
The role of cytidine deaminase and GATA1 mutations in the increased cytosine arabinoside sensitivity of Down syndrome myeloblasts and leukemia cell lines. Cancer Res (2004) 1.07
New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia. Cell Signal (2013) 1.07
High frequency of leukemic clones in newborn screening blood samples of children with B-precursor acute lymphoblastic leukemia. Blood (2002) 1.05
Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. PLoS One (2013) 1.03
Localization of a substrate binding domain of the human reduced folate carrier to transmembrane domain 11 by radioaffinity labeling and cysteine-substituted accessibility methods. J Biol Chem (2005) 1.03
The human reduced folate carrier gene is regulated by the AP2 and sp1 transcription factor families and a functional 61-base pair polymorphism. J Biol Chem (2002) 1.01
Protection of NRK-52E cells, a rat renal proximal tubular cell line, from chemical-induced apoptosis by overexpression of a mitochondrial glutathione transporter. J Pharmacol Exp Ther (2002) 1.01
Modulation of expression of rat mitochondrial 2-oxoglutarate carrier in NRK-52E cells alters mitochondrial transport and accumulation of glutathione and susceptibility to chemically induced apoptosis. J Pharmacol Exp Ther (2005) 0.99
Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia. Cancer (2013) 0.98
Identification and functional impact of homo-oligomers of the human proton-coupled folate transporter. J Biol Chem (2011) 0.97
Retroperitoneal malignant peripheral nerve sheath tumor: evaluation with serial FDG-PET. Clin Nucl Med (2004) 0.95
Analysis of membrane topology of the human reduced folate carrier protein by hemagglutinin epitope insertion and scanning glycosylation insertion mutagenesis. Biochim Biophys Acta (2002) 0.95
Roles of USF, Ikaros and Sp proteins in the transcriptional regulation of the human reduced folate carrier B promoter. Biochem J (2004) 0.94
Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines. Blood (2002) 0.94
Functional loss of the reduced folate carrier enhances the antitumor activities of novel antifolates with selective uptake by the proton-coupled folate transporter. Mol Pharmacol (2012) 0.94
Parent communication and child pain and distress during painful pediatric cancer treatments. Soc Sci Med (2006) 0.92
Transmembrane domains 4, 5, 7, 8, and 10 of the human reduced folate carrier are important structural or functional components of the transmembrane channel for folate substrates. J Biol Chem (2006) 0.92
Effects of 5' untranslated region diversity on the posttranscriptional regulation of the human reduced folate carrier. Biochim Biophys Acta (2007) 0.92
Oligomeric structure of the human reduced folate carrier: identification of homo-oligomers and dominant-negative effects on carrier expression and function. J Biol Chem (2008) 0.91
Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer. PLoS One (2012) 0.91
Longitudinal study of parent caregiving self-efficacy and parent stress reactions with pediatric cancer treatment procedures. Psychooncology (2012) 0.90
Restoration of transport activity by co-expression of human reduced folate carrier half-molecules in transport-impaired K562 cells: localization of a substrate binding domain to transmembrane domains 7-12. J Biol Chem (2004) 0.90
Acute leukemia in children with Down syndrome. Haematologica (2010) 0.90
CHK1 plays a critical role in the anti-leukemic activity of the wee1 inhibitor MK-1775 in acute myeloid leukemia cells. J Hematol Oncol (2014) 0.90
Effect of body mass index on the outcome of children with acute myeloid leukemia. Cancer (2012) 0.90
5,10-methylenetetrahydrofolate reductase (MTHFR) polymorphisms and the risk of acute lymphoblastic leukemia (ALL) in Filipino children. Pediatr Blood Cancer (2008) 0.89
Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity. J Biol Chem (2003) 0.89
Transcription factor GATA-1 and Down syndrome leukemogenesis. Leuk Lymphoma (2006) 0.88
Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia. Pediatr Blood Cancer (2014) 0.88
Prognostic role of the reduced folate carrier, the major membrane transporter for methotrexate, in childhood acute lymphoblastic leukemia: a report from the Children's Oncology Group. Clin Cancer Res (2007) 0.87
Temperament, personality, and quality of life in pediatric cancer patients. J Pediatr Psychol (2014) 0.87
Characterization of a cysteine-less human reduced folate carrier: localization of a substrate-binding domain by cysteine-scanning mutagenesis and cysteine accessibility methods. Biochem J (2003) 0.87
Identification of the minimal functional unit of the homo-oligomeric human reduced folate carrier. J Biol Chem (2009) 0.87
Children with hyperdiploid but not triple trisomy (+4,+10,+17) acute lymphoblastic leukemia have an increased incidence of extramedullary relapse on current therapies: a single institution experience. Am J Hematol (2008) 0.87
Tumor-targeting with novel non-benzoyl 6-substituted straight chain pyrrolo[2,3-d]pyrimidine antifolates via cellular uptake by folate receptor α and inhibition of de novo purine nucleotide biosynthesis. J Med Chem (2013) 0.86
Panobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cells. PLoS One (2013) 0.86
Synergistic regulation of human cystathionine-beta-synthase-1b promoter by transcription factors NF-YA isoforms and Sp1. Biochim Biophys Acta (2002) 0.86
Age-related loss of the DNA repair response following exposure to oxidative stress. J Gerontol A Biol Sci Med Sci (2006) 0.86
Primary acute lymphoblastic leukemia cells use a novel promoter and 5'noncoding exon for the human reduced folate carrier that encodes a modified carrier translated from an upstream translational start. Clin Cancer Res (2004) 0.86
Treatment outcome in older patients with childhood acute myeloid leukemia. Cancer (2012) 0.86
Therapeutic targeting malignant mesothelioma with a novel 6-substituted pyrrolo[2,3-d]pyrimidine thienoyl antifolate via its selective uptake by the proton-coupled folate transporter. Cancer Chemother Pharmacol (2013) 0.86
Prognostic factors in children with acute myeloid leukaemia and excellent response to remission induction therapy. Br J Haematol (2014) 0.84
Development of acute megakaryoblastic leukemia in Down syndrome is associated with sequential epigenetic changes. Blood (2013) 0.84
Acute leukemias in children with Down syndrome. Mol Genet Metab (2012) 0.84
Role of rat organic anion transporter 3 (Oat3) in the renal basolateral transport of glutathione. Chem Biol Interact (2007) 0.83
Reduced folate carrier mutations are not the mechanism underlying methotrexate resistance in childhood acute lymphoblastic leukemia. Cancer (2004) 0.83
Role of lysine 411 in substrate carboxyl group binding to the human reduced folate carrier, as determined by site-directed mutagenesis and affinity inhibition. Mol Pharmacol (2008) 0.83
Implications of plasma protein binding for pharmacokinetics and pharmacodynamics of the γ-secretase inhibitor RO4929097. Clin Cancer Res (2012) 0.83
Analysis of the membrane topology for transmembrane domains 7-12 of the human reduced folate carrier by scanning cysteine accessibility methods. Biochem J (2004) 0.82
Transcriptional regulation of the human reduced folate carrier A1/A2 promoter: Identification of critical roles for the USF and GATA families of transcription factors. Biochim Biophys Acta (2005) 0.82
Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells. Pediatr Blood Cancer (2012) 0.82
Acute megakaryoblastic leukemia without GATA1 mutation after transient myeloproliferative disorder in an infant without Down syndrome. J Clin Oncol (2011) 0.81
Post-transcriptional regulation of the human reduced folate carrier as a novel adaptive mechanism in response to folate excess or deficiency. Biosci Rep (2014) 0.81